AbCellera grabs USD 105 Million for series B funding round.
AbCellera has grabbed a significant USD 105 million series B funding round. The funding will help its antibody work and quest for new potential meds against COVID-19.
Gilead inks USD 2 Billion deal with Arcus.
Gilead Sciences is paying USD 175 million upfront with a USD 200 million equity investment weighted in. Arcus Biosciences could also catch up to USD 1.225 billion in opt-in and milestone payments to its present clinical product drugs.
GlaxoSmithKline’s anti-BCMA antibody receives a boost.
BCMA-targeting medicine of GlaxoSmithKline shrank tumors in one-third of patients with advanced multiple myeloma. The antibody-drug conjugate (ADC) is filling its case as the British drugmaker waits for the agency’s decision now.
The startup focuses on glioblastoma tumors with CAR-T therapy.
The scientists at McMaster University and the University of Toronto have developed a CAR-T therapy for the aggressive brain cancer glioblastoma. It aided in reducing the burden of the tumour and enhanced survival in mouse models as published in the journal Cell Stem Cell.
For more information visit: